The bill amends the Federal Food, Drug, and Cosmetic Act to add explicit caffeine disclosure rules for both retail food service and packaged foods and dietary supplements. For chain restaurants (20+ locations) it requires menu disclosures and a conspicuous 'High caffeine' marker for items with added caffeine at or above 150 mg per serving; for packaged foods and supplements, any product with more than 10 mg of caffeine must state the milligrams present, whether the caffeine is natural or added, and include an advisory citing a 400 mg daily limit (or an alternative set by the Secretary).
Beyond labeling, the measure directs the FDA to review whether caffeine and certain stimulant blends are GRAS and orders the NIH to review effects on vulnerable populations; it also funds a public‑education campaign and a GAO study on marketing to children. The package is a quick, federally uniform push to increase consumer information about caffeine that will trigger testing, new disclosures, potential reformulations, and additional agency rulemaking or guidance.
At a Glance
What It Does
Adds menu‑labeling requirements for chain restaurants (20+ locations), including a 'High caffeine' designation for items with at least 150 mg of added caffeine, and requires packaged foods and dietary supplements with >10 mg caffeine to list milligrams, source (natural or added), and a daily‑limit advisory. It also instructs FDA and NIH to conduct safety reviews and funds a public education campaign and a GAO study on marketing practices.
Who It Affects
National restaurant chains with 20 or more locations; manufacturers and packagers of foods and dietary supplements that contain caffeine; federal agencies (FDA, NIH, CDC) and the GAO; and marketing firms and social‑media channels that promote caffeinated beverages.
Why It Matters
It converts caffeine exposure into countable, on‑product metrics and ties federal scientific review to labeling thresholds—creating a pathway for regulatory change. Companies will need to quantify caffeine content, update labels and menus, and possibly reformulate products; public‑health actors will gain new evidence and tools to address youth exposure.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The Act tightens what consumers see about caffeine both at point of sale and on packaged goods. For restaurants and similar retail food establishments that are part of chains with 20 or more locations operating under the same name, the bill folds caffeine into existing menu‑labeling requirements.
It requires that a menu listing show the number of milligrams of caffeine in an item and that any standard or temporary menu item containing added caffeine and at least 150 mg per serving carry a clear 'High caffeine' statement or a symbol adjacent to the item name. Temporary items are defined as those appearing fewer than 60 days per calendar year and have a slightly narrower disclosure duty.
For packaged foods and dietary supplements, the bill creates a new labeling trigger at 10 mg of caffeine. Any product above that threshold must list the caffeine content in milligrams, say whether the caffeine is naturally occurring or an additive, and display an advisory that cites a 400 mg daily limit for healthy adults (subject to revision by the Secretary).
Those requirements attach directly to the product label under the misbranding provisions of the FD&C Act.The measure also orders two federal scientific reviews. The FDA must rapidly evaluate whether caffeine (and certain stimulant blends and ingredients such as guarana and taurine) remains generally recognized as safe (GRAS) for healthy populations, consider thresholds for safety, and report findings to Congress within six months.
The NIH must review caffeine’s effects on specified vulnerable groups—children and adolescents, people with heart conditions, pregnant and breastfeeding people, those with seizure disorders or stimulant‑sensitive mental health conditions, and other groups the Director identifies—and also report in six months. Each review has a $1 million authorization.To support behavioral change and monitor industry practices, the bill requires a public education campaign run by FDA with CDC input focused on overconsumption risks and youth marketing patterns, and it directs the GAO to study how caffeinated beverages are marketed, including online and via influencers, with a report due in 180 days.
Together these measures create immediate labeling obligations and lay the groundwork for further agency action based on the scientific reviews and GAO findings.
The Five Things You Need to Know
Chain restaurants with 20 or more locations must disclose milligrams of caffeine on menus and menu boards and mark items with added caffeine ≥150 mg per serving as 'High caffeine'.
Packaged foods and dietary supplements containing more than 10 mg of caffeine must list the milligrams, state whether the caffeine is naturally occurring or added, and include an advisory citing 400 mg as the daily recommended limit (or Secretary’s alternative).
The FDA must complete a review on whether caffeine and certain stimulant blends are GRAS, consider safety thresholds and whether rules are needed, and report to Congress within 6 months.
The NIH must review caffeine’s effects on named vulnerable populations (children and adolescents; pregnant and breastfeeding people; people with heart or seizure disorders; certain mental‑health conditions; caffeine‑sensitive individuals) and report to Congress within 6 months; each review has a $1 million authorized appropriation.
The bill requires a federal public education campaign on caffeine safety (FDA/CDC) and a GAO study on marketing—especially targeting of youth and misleading practices—with the GAO report due within 180 days.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Menu labeling changes for chains and temporary items
This section amends the existing menu‑labeling provision of the FD&C Act to fold caffeine into disclosure rules for chains with 20 or more locations. It requires the milligram amount of caffeine to appear on menus and menu boards and creates a new conspicuous 'High caffeine' indicator for standard or temporary menu items that contain added caffeine and at least 150 mg per serving. Temporary menu items—those appearing fewer than 60 days per year—must meet a subset of the disclosure duties. Practically, chains will need to measure caffeine levels in their recipes, update printed and digital menus (including drive‑through boards), and adopt a label or symbol that is clearly associated with qualifying items.
Packaged food and dietary supplement labeling requirement
Adds a new subsection to FD&C section 403 that triggers mandatory on‑label disclosures for any food or dietary supplement with more than 10 mg of caffeine. Labels must state the number of milligrams of caffeine, whether the caffeine is naturally occurring or added, and carry an advisory stating a 400 mg daily recommended limit (subject to Secretary adjustment). That creates a low‑threshold labeling obligation affecting beverages and many foods and supplements, requiring manufacturers to quantify and declare caffeine on Nutrition Facts or Supplement Facts panels or adjacent labeling.
FDA review of caffeine and stimulant blends (GRAS evaluation)
Directs the FDA Commissioner to conduct a time‑limited review of caffeine and related stimulants in food and dietary supplements with a focus on whether caffeine qualifies as GRAS for healthy populations, the safety of added caffeine and complex stimulant blends, the safety of guarana and taurine when added, and appropriate quantitative thresholds. The Commissioner must report findings to Congress within six months and may use results to inform labeling thresholds and potential regulatory action. The provision signals that labeling changes could be followed by substantive regulatory steps depending on the science.
NIH review on vulnerable populations and funding
Requires the NIH Director to evaluate caffeine’s effects on enumerated vulnerable groups—children and adolescents, people with underlying heart conditions, pregnant and breastfeeding people, individuals with seizure disorders, those with stimulant‑sensitive mental‑health conditions, and other groups the Director selects. The Director may contract the work out and must submit a report within six months. Congress authorized $1 million for the FDA review and $1 million for the NIH review; these sums are modest, intended to support rapid assessments rather than long‑term research programs.
Public education campaign on caffeine safety
Mandates that FDA, in consultation with CDC and in partnership with consumer and patient groups, run an education campaign focused on safe caffeine consumption, the special risks to vulnerable groups, how caffeine is marketed to youth, and how stimulants like guarana and taurine affect safety. This is an implementation vehicle to translate labeling and review findings into public messaging; it will require coordination across agencies and external partners to shape outreach and materials.
GAO study on marketing of caffeinated beverages
Directs the Comptroller General to study and report within 180 days on how caffeinated beverages are marketed in restaurants, stores, and online—explicitly including social media and influencer promotion. The focus is on misleading claims and youth targeting, and the report must include recommendations for legislative or administrative action. The GAO study could be a precursor to enforcement or further statutory limits on certain marketing practices.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Consumers who want clearer information: Milligram disclosures and a 'High caffeine' marker let adults make dosage‑aware choices at the point of sale and when buying packaged products.
- Parents, pediatricians, and school health officials: The labeling and the GAO study’s focus on youth marketing give these stakeholders tools to identify and reduce adolescent exposure to marketed, high‑dose caffeinated products.
- Public‑health agencies and researchers: FDA and NIH reviews plus GAO findings will generate consolidated data and official assessments that can inform guidance, surveillance, and targeted interventions.
- Advocacy and patient groups: The required public education campaign and formal reviews create opportunities to advance prevention messaging and secure stakeholder input during federal outreach.
Who Bears the Cost
- National restaurant chains (20+ locations): They must analyze recipes for caffeine content, change menus and digital boards (including drive‑through), and implement a 'High caffeine' labeling system—operational and compliance costs concentrated at scale.
- Manufacturers of food and dietary supplements: Any product with >10 mg caffeine will need label modifications and may need additional testing or formulation changes to comply with the new milligram‑disclosure and source‑of‑caffeine requirements.
- Federal agencies (FDA, NIH, CDC): Although $1 million each is authorized, agencies must reallocate staff time and possibly seek more funds to do thorough reviews, enforce labeling, and run an effective education campaign.
- Marketers and social‑media promoters: The GAO study increases scrutiny of youth‑targeted tactics and influencer promotion, and may precipitate tighter administrative controls or consumer backlash.
- Producers of stimulant blends and ingredient suppliers: Manufacturers using guarana, taurine, or concentrated caffeine blends may face reformulation pressure, new testing protocols, or limits based on the FDA’s GRAS review.
Key Issues
The Core Tension
The central dilemma is between rapidly giving consumers clearer, standardized information about caffeine exposure—particularly to protect children and vulnerable adults—and imposing potentially large compliance, testing, and reformulation burdens on industry while acting on scientific questions that may not be settled; faster labeling and advisory action improves transparency but risks mismatches between policy thresholds and varied individual risk.
The bill creates clear disclosure obligations but leaves several implementation details to the Secretary’s rulemaking or guidance, which raises practical questions. Determining when caffeine is "added" versus "naturally occurring" can be ambiguous (for example, brewed tea or chocolate versus concentrated extracts), and manufacturers will need standardized testing or calculation methods to report consistent milligram amounts.
The 10 mg threshold for packaged goods is low enough to capture many commonly consumed items, potentially expanding labeling obligations broadly and requiring operational changes across beverage and food sectors.
The chosen quantitative triggers—10 mg for packaged labels and 150 mg for the 'High caffeine' menu marker—represent policy judgments that may not map cleanly onto risk across all populations. The advisory statement cites a single 400 mg daily limit for healthy adults while the NIH review specifically targets vulnerable groups; if NIH finds lower safe limits for those groups, regulators will face the awkward task of harmonizing a universal advisory with subgroup‑specific guidance.
Finally, the appropriations are modest and the statutory deadlines (two 6‑month reports, one 180‑day GAO report) push for quick outputs that could produce preliminary conclusions requiring follow‑up, and the reliance on agency discretion for symbols, phrasing, and enforcement approaches leaves room for litigation and compliance uncertainty.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.